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srug-eluting stents have been the most successful strategy
or the prevention of restenosis after percutaneous coronary
nterventions (1). In line with this, the STRATEGY
Single High-Dose Bolus Tirofiban and Sirolimus Eluting
tent versus Abciximab and Bare Metal Stent in Acute
yocardial Infarction) study showed a marked decrease in
he need for reintervention with sirolimus-eluting stents
SES) as compared with bare-metal stents (BMS) even in
he high-risk subset of patients with acute myocardial
nfarction (AMI) (2). Although the STRATEGY trial
imultaneously evaluated the impact of another factor,
lycoprotein IIb/IIIa inhibition with abciximab or tirofiban,
his trial is now predominantly considered an SES versus
MS trial. In fact, there is no reason to believe that the type
f glycoprotein IIb/IIIa inhibitor (3) had an important
See page 138
ole in the difference in reintervention rates between the
ES and BMS groups observed in the STRATEGY trial
2). In addition, the main 8-month results of the STRAT-
GY trial have been corroborated by a larger SES versus
MS trial in patients with AMI (4). Cardiologists have
lways been concerned with the sustainability of the initially
ositive results achieved with various drugs and devices.
hus, it is fully conceivable that the investigators of the
TRATEGY trial were interested to know whether the
dvantages observed within 8 months of randomization
ith SES (2) are maintained beyond this time frame. In this
ssue of the Journal, Valgimigli et al. (5) assessed if the initial
linical benefit with SES is also demonstrable after 2 years.
ith this, they mark a second important achievement in
heir career: they were the first to evaluate SES in patients
ith AMI (2) and also become the first to report on this
ssue beyond 1 year (5).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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tudy is yes, the midterm benefit achieved with SES is
aintained over 2 years. Indeed, the authors showed that SES
ontinued to be associated with a significantly reduced risk of
eintervention with a hazard ratio of 0.34 at 2 years (5), which
s not different from that of 0.30 shown at 8 months (2). Also,
he result regarding the composite of death and myocardial
nfarction was maintained between 8 months and 2 years: in
oth time points, SES did not impact significantly on the risk
f death or myocardial infarction, with a hazard ratio of 0.77 at
years (5) versus 0.71 at 8 months (2).
Although the 2-year analysis of the STRATEGY trial
learly showed that the benefit achieved by SES at 8 months is
ustained over 2 years, this analysis contributes less to the
urrent discussion on the safety of drug-eluting stents. Current
ncertainties are best illustrated in the figure included in a
ecent editorial presenting restenosis as the typical potential
isk for BMS and thrombosis as the typical potential risk for
rug-eluting stents (6). The 2-year report of the STRATEGY
rial showed no significant differences in stent thromboses and
ortality between SES and BMS, but, with only 2 stent
hromboses and 22 death cases, this study has very limited
ower to help us eliminate existing concerns (5). In fact, no
ingle SES versus BMS randomized trial has had sufficient
ower to assess this issue (7). Therefore, using single trials such
s STRATEGY or a combination of a few of them as done in
he recent past (8) may be misleading in the evaluation of
ong-term safety of drug-eluting stents. The 2-year results of
he STRATEGY trial should be validated in the context of all
vailable safety information from randomized SES versus
MS trials. Figure 1 presents a meta-analysis of stent throm-
osis in 17 randomized trials including 5,606 patients who
ere randomly assigned to SES or BMS. Using the protocol-
efined criteria for stent thrombosis as well as the longest
vailable follow-up in each trial, there were 37 cases of stent
hrombosis with SES and 38 with BMS, which corresponds to
pooled relative risk of 0.99 (95% confidence interval [CI]
.61 to 1.61). These findings do not support the largely
iffused concerns about a higher risk of stent thrombosis with
ES compared with BMS. The basis of these concerns are not
nly pathological data on delayed healing with drug-eluting
tents (9) but, most importantly, reports based on analyses of
elected trials. In a recent analysis including only 4 SES versus
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July 10, 2007:146–8 Editorial CommentMS trials with a total of 15 protocol-defined stent thrombo-
es, Stone et al. (10) described an excessive risk of stent
hrombosis with SES after 1 year as illustrated by its occurrence
n 5 patients with SES and none with BMS (p  0.025). A
ossible selection bias and differences in the definition criteria
f stent thrombosis across trials have contributed to these
pparently controversial results. For example, in the 4 trials
nalyzed in the aforementioned analysis (10), patients under-
oing reintervention were censored from further analysis of
tent thrombosis. This led to the exclusion of 5 cases of stent
hrombosis that had occurred among BMS patients after a
eintervention (7). The following case from those 4 trials may
llustrate par excellence the nonsense to which questionable
efinitions and post-hoc adjudication of events may lead. In a
atient who received a BMS, stent thrombosis was not ac-
ounted for because it occurred after a reintervention for restenosis,
hich, in its turn, was not accounted for as a reintervention by the
djudication committee because of missing evidence of isch-
mia. Thus, 2 events that actually occurred do not appear in
ny of the previously published analyses.
Mortality certainly represents the most unbiased measure of
rug-eluting stent safety. In the STRATEGY trial, there were
0 death cases in the SES group versus 12 death cases in the
MS group. These are small numbers, but the result is in line
ith the pooled result of the meta-analysis shown in Figure 2.
here were 150 deaths in the SES group and 156 deaths in the
MS group, which corresponds to a pooled relative risk of 1.00
95% CI 0.80 to 1.26). This is in full contrast with the 18%
ncrease in the risk of death with drug-eluting stents reported
Figure 1 RRs for Stent Thrombosis in 17 Randomized Trials Co
The source of the trials may be found in Kastrati et al. (7). BMS  bare-metal ste
CI  confidence interval; FU  follow-up; RR  relative risk; SES  sirolimus-elutiecently from a registry study (11), providing the umpteenth testimony of how inaccurate registries might be for the com-
arative evaluation of 2 treatment strategies.
On-label use of SES is indicated in patients with symptom-
tic ischemic disease but without AMI for de novo lesions of
ength 30 mm in native coronary arteries with a reference
essel diameter between 2.5 and 3.5 mm. Therefore, the
ositive results shown in the STRATEGY trial should be seen
n the context of a typical example of off-label use of SES. Of
he 17 trials included in the analyses shown in Figures 1 and 2,
nly 4 addressed on-label use of SES, and the remaining 13
rials represented off-label indications. For on-label indications,
ES was associated with relative risk of 1.04 (95% CI 0.75 to
.46) for death and 1.60 (95% CI 0.53 to 4.82) for stent
hrombosis; for off-label indications, SES was associated with
relative risk of 0.97 (95% CI 0.70 to 1.33) for death and 0.88
95% CI 0.51 to 1.52) for stent thrombosis. Thus, there is no
vidence at all that off-label use of SES is associated with
ompromised safety compared with BMS. This is very reas-
uring considering that off-label use often involves subsets
chronic occlusions, very long lesions, lesions in small vessels)
hat carry the highest risk for restenosis and may benefit the
ost from drug-eluting stents. These considerations may help
o discourage the current trend to prevent off-label use of
rug-eluting stents driven by some irreproducible findings
oming exactly from on-label use of them.
The patients who received SES in the STRATEGY trial
ere treated with thienopyridines (ticlopidine or clopi-
ogrel) for an average of 6 months after the procedure.
ptimal duration of thienopyridine therapy after implanta-
ing SES With BMS
nt.mpar
nt;
ng steion of drug-eluting stents is not known. Although specific
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Editorial Comment July 10, 2007:146–8tudies on this topic are lacking, recent recommendations
all for at least a 1-year duration (12).
In summary, drug-eluting stents are still a young tech-
ology with many unknowns, but also with a great potential
or improvement. Initial optimism that claimed elimination
f restenosis with drug-eluting stents is not supported by
bundant evidence showing that restenosis is far from being
ompletely defeated by current technology. However,
merging skepticism about late safety of drug-eluting stents
s not justified by available evidence regarding long-term
utcomes of patients treated with this therapy. The 2-year
esults of the STRATEGY trial are the most recent
onfirmation of this. Both unjustified optimism and skep-
icism may be equally harmful to patients with coronary
rtery disease. We should resist the temptation common to
he lay media of prematurely proclaiming both the success
nd failure of a treatment strategy. Drug-eluting stents may
ave lost in brightness but not in real value.
eprint requests and correspondence: Dr. Adnan Kastrati,
eutsches Herzzentrum, Lazarettstr. 36, 80636 Munich, Ger-
any. E-mail: kastrati@dhm.mhn.de.
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